<Blinded Review: TIME_ANON_0952>
**Composite Score:** 3.1 / 10.0 (Rigor: 0.8/3.5 | Claims: 0.8/2.5 | Biology: 0.7/2.0 | Reproducibility: 0.8/2.0)
**Bias Category:** Statistical/Design
**Verdict:** Reject (Fundamental Flaws)
**Study Modality:** Hybrid Computational + Wet-Lab
**Technology Maturity:** Mature/Classical
**Epistemic Stage:** Clinical/Observational

OVERALL_SCORE: 3.1/10
VERDICT: FAILED
ESTIMATED_DECADE: 2000s

---

### 1. Executive Summary / SUMMARY
This pharmacogenetics study genotypes five common single-nucleotide polymorphisms (`G191A` `rs1801279`, `C481T` `rs1799929`, `G590A` `rs1799930`, `A803G` `rs1208`, and `G857A` `rs1799931`) in the phase II xenobiotic-metabolizing enzyme gene *NAT2* using PCR-RFLP (`MspI`, `KpnI`, `TaqI`, `DdeI`, `BamHI`) in $N=183$ healthy blood donors from Ilhéus, Bahia, Northeastern Brazil, stratified by self-reported ancestry into Afro-Brazilians ($68.31\%$, $n=125$), Whites ($15.30\%$, $n=28$), and Tupinambá Amerindians ($16.39\%$, $n=30$). Using $\chi^2$ tests, logistic regression (`SPSS` v15.0, `UNPHASED` v3.0.13), and `HAPLOVIEW` v4.1, the authors report no significant differences between Afro-Brazilians and Whites, but a higher frequency of the `590A` slow-acetylator allele and a specific `G590A–A803G` LD block in the Amerindian subgroup. However, forensic audit of Tables 1–4 reveals pervasive arithmetic, statistical, and biochemical errors across every single data table in the manuscript.

### 2. Methodological & Statistical Audit / STRENGTHS & WEAKNESSES & METHODOLOGICAL AUDIT

#### STRENGTHS
- **Clear PCR-RFLP Genotyping Protocol:** Primer sequences, restriction enzymes, and gel electrophoresis conditions for the 895-bp *NAT2* amplicon are clearly described.
- **Relevant Admixed Population Context:** Studying pharmacogenetic variation in tri-hybrid admixed Brazilian cohorts is clinically relevant for isoniazid and dapsone therapy.

#### WEAKNESSES & METHODOLOGICAL AUDIT
- **Pervasive Arithmetic Failure in Genotype and Allele Counts (Table 2):**
  In Table 2, the cohort consists of $N=183$ individuals: 125 Afro-Brazilians ($68.31\%$), 28 Whites ($15.30\%$), and 30 Amerindians ($16.39\%$). Yet in **every single SNP in Table 2**, the sum of the three ethnic groups fails to equal the reported `Total` column:
  1. **`G191A`:** `GG` across groups is $104 + 23 + 27 = 154$ (reported `Total` = `158`); `GA` is $20 + 4 + 3 = 27$ (reported `Total` = `22`); `AA` is $1 + 1 + 0 = 2$ (reported `Total` = `3`). Worse still, in the `Total` allele rows for `G191A`, the authors report **`G = 28` and `A = 338`**—inverting the wild-type `G` and mutant `A` alleles (and even inverted, $228 + 50 + 57 = 335$ `G` alleles and $22 + 6 + 3 = 31$ `A` alleles, not 338 and 28!).
  2. **`C481T`:** `CC` across groups is $41 + 11 + 12 = 64$ (reported `Total` = `72`); `CT` is $60 + 15 + 10 = 85$ (reported `Total` = `79`); `TT` is $23 + 2 + 8 = 33$ (reported `Total` = `31`).
  3. **`G590A`:** `GG` across groups is $77 + 19 + 10 = 106$ (reported `Total` = `92`); `GA` is $46 + 8 + 14 = 68$ (reported `Total` = `67`); `AA` is $2 + 1 + 6 = 9$ (reported `Total` = `24`!). Furthermore, in the text (line 141), the authors claim the `590A` allele frequency in Amerindians is `42.5%` and in Whites is `19.4%`, whereas in Table 2, Amerindians have $26 / (34+26) = 43.3\%$ and Whites have $10 / (46+10) = 17.9\%$.
  4. **`A803G`:** `AA` across groups is $64 + 15 + 17 = 96$ (reported `Total` = `107`); `AG` is $61 + 11 + 12 = 84$ (reported `Total` = `73`). Moreover, line 60 claims the `GG` genotype was found in Whites and Amerindians at *"6.1 and 3.4%, respectively"*, whereas in Table 2 `GG` is $2/28 = 7.1\%$ in Whites and $1/30 = 3.3\%$ in Amerindians.
  5. **`G857A`:** `AA` across groups is $6 + 1 + 0 = 7$ (reported `Total` = `3`); `GA` is $33 + 10 + 6 = 49$ (reported `Total` = `51`); `GG` is $86 + 17 + 24 = 127$ (reported `Total` = `129`). Furthermore, line 60 erroneously refers to `AA` as *"homozygous carriers of G857A wild allele (AA)"* when `G` is the wild-type allele and `A` is the mutant allele!
- **Mathematically Impossible Odds Ratios, Confidence Intervals, and $p$-Values (Table 3):**
  1. For `191A` in Amerindians (Table 3), the authors report `OR = 0.22 (CI 95%: 0.28–1.76), p3 = 0.0003`. First, an odds ratio point estimate (`0.22`) **cannot lie outside its own 95% confidence interval (`0.28–1.76`)**! Second, a 95% CI of `0.28–1.76` broadly crosses the null value of `1.0` (corresponding to $p \approx 0.31$ as in Table 2), making a two-tailed $p$-value of `0.0003` (with only 3 mutant alleles in $n=30$ Amerindians vs 22/250 in Afro-Brazilians and 6/56 in Whites!) mathematically impossible.
  2. For `590A` in Amerindians (Table 3 and Abstract/Results line 59), the authors report `OR = 3.71 (CI 95%: 0.28–8.54), p3 = 0.040`. A 95% CI spanning from `0.28` to `8.54` includes `1.0` by a wide margin and cannot have a two-tailed Wald/LR $p = 0.040$; conversely, in Afro-Brazilians for `590A`, `OR = 0.33 (CI 95%: 0.12–0.95)` *excludes* `1.0` yet is reported as `p1 = 0.317`!
  3. For `857A` in Amerindians (Table 3), the authors report `OR = 0.39 (CI 95%: 0.05–2.89), p3 = 0.003`. Again, a 95% CI of `0.05–2.89` broadly overlaps `1.0` (consistent with Table 2's $p = 0.1373$), making $p = 0.003$ impossible.
- **Severe Tally Discrepancies in Haplotype Table 4 and Flawed Phenotype Definition:**
  1. In Table 4, the sum of haplotypes across Afro-Brazilians, Whites, and Amerindians does not match the `Total` column in **any row** (e.g., Haplotype B: $6 + 4 + 3 = 13$ vs `Total = 35`; Haplotype C: $3 + 1 + 7 = 11$ vs `Total = 23`; Haplotype D: $5 + 2 + 2 = 9$ vs `Total = 23`), and the total number of phased chromosomes in the ethnic columns sums to only 54 Afro-Brazilians, 23 Whites, and 22 Amerindians out of $2N = 366$ chromosomes!
  2. In lines 130–132 and Table 4, the authors define "Slow Acetylator Haplotype" as any haplotype carrying `191A` or `590A` while *excluding* `857A` (`NAT2*7A/*7B`, Haplotype F), yet then include Haplotype J (`G-T-G-A-A`, which carries `857A` and neither `191A` nor `590A`) in their list of slow haplotypes (`C, E, I, J, and L`) while excluding Haplotype G (`A-C-G-A-G`, which carries `191A`) and Haplotype K (`857A`)!
  3. In Table 1, `G857A` (`rs1799931`) is listed as amino acid substitution `Gly286Gln`, which is biochemically impossible via a single `G>A` nucleotide substitution (glycine `GGA` $\rightarrow$ glutamic acid `GAA`, `Gly286Glu`).

### 3. Biological / Experimental Grounding & Claim Proportionality
- **Claim 1:** Afro-Brazilians and Whites in Ilhéus show no significant difference in *NAT2* allele frequencies due to historical admixture. `[Moderately Supported]` — Supported by the group counts in Table 2, though White sample size ($n=28$) is very small and self-reported skin color in Bahia is a weak proxy for genomic ancestry.
- **Claim 2:** Amerindians have significantly higher `590A` (`OR = 3.71, 95% CI = 0.28–8.54, p = 0.040`) and lower `191A` (`OR = 0.22, 95% CI = 0.28–1.76, p = 0.0003`) and `857A` (`OR = 0.39, 95% CI = 0.05–2.89, p = 0.003`) in logistic regression. `[Methodologically Flawed]` — Every reported odds ratio/CI/$p$-value triplet in Table 3 is internally inconsistent, and the subgroup sample sizes ($n=28$ Whites, $n=30$ Amerindians) are severely underpowered.
- **Claim 3:** Slow acetylator haplotypes are 44.9% in Amerindians vs 22.9% in Afro-Brazilians and 25.8% in Whites (Table 4). `[Methodologically Flawed]` — Based on a contradictory slow-haplotype classification rule and Table 4 counts that do not sum to the cohort totals.

### 4. Reproducibility & Data Completeness
- **Internal Data Integrity:** Fails basic arithmetic and statistical verification across Tables 1, 2, 3, and 4. Raw individual-level genotypes would be required to recompute the correct contingency tables, odds ratios, and EM haplotype frequencies.
</Blinded Review: TIME_ANON_0952>
